Cangene (FRA:YGE) Treasury Stock : €0.00 Mil (As of Oct. 2013)

View and export this data going back to . Start your Free Trial

What is Cangene Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Cangene's treasury stock for the quarter that ended in Oct. 2013 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Cangene Treasury Stock Historical Data

The historical data trend for Cangene's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cangene Treasury Stock Chart

Cangene Annual Data

Trend

Jul04

Jul05

Jul06

Jul07

Jul08

Jul09

Jul10

Jul11

Jul12

Jul13

Treasury Stock

Get a 7-Day Free Trial

Cangene Quarterly Data
	Jan09	Apr09	Jul09	Oct09	Jan10	Apr10	Jul10	Oct10	Jan11	Apr11	Jul11	Oct11	Jan12	Apr12	Jul12	Oct12	Jan13	Apr13	Jul13	Oct13
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Cangene Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Cangene (FRA:YGE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cangene Corporation (FRA:YGE) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cangene.com

Cangene Corporation is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. The company manages its business and evaluate performance based on two operating segments: biopharmaceutical operations and contract services. Revenues are generated from product sales, and contract manufacturing and contract-R&D services.

Cangene (FRA:YGE) Headlines

No Headlines